共 101 条
[21]
Figueroa-Vadillo J(1988)Dose-ranging evaluation of the serotonin antagonist GR-C507/75 (GR38032F) when used as an antiemetic in patients receiving anticancer chemotherapy J Clin Oncol 6 659-662
[22]
Zamora R(2006)American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006 J Clin Oncol 24 2932-2947
[23]
Erazo Valle A(2005)Incidence of chemotherapy-induced nausea and vomiting in Taiwan: physicians’ and nurses’ estimation vs. patients’ reported outcomes Support Care Cancer 13 277-286
[24]
Wisniewski T(2007)Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients Cancer Chemother Pharmacol 59 407-412
[25]
Figueroa Vadillo JI(2005)Evidence-based recommendations for the use of antiemetics in radiotherapy Radiother Oncol 76 227-233
[26]
Ettinger DS(2003)Effects of the neurokinin-1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone Clin Pharmacol Ther 74 17-24
[27]
Bierman PJ(2008)One-month adherence in children with new-onset epilepsy: white-coat compliance does not occur Pediatrics 121 e961-e966
[28]
Bradbury B(1999)Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group N Engl J Med 340 190-195
[29]
Gralla R(2005)Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients Cancer Chemother Pharmacol 55 609-616
[30]
Lichinitser M(2008)Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer J Clin Oncol 26 556-562